about
Nitric oxide donor upregulation of stromal cell-derived factor-1/chemokine (CXC motif) receptor 4 enhances bone marrow stromal cell migration into ischemic brain after strokeComparison of bone marrow stromal cells derived from stroke and normal rats for stroke treatment.Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcomeEndothelial nitric oxide synthase regulates white matter changes via the BDNF/TrkB pathway after stroke in miceTreatment of stroke with (Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl) amino] diazen-1-ium-1, 2-diolate and bone marrow stromal cells upregulates angiopoietin-1/Tie2 and enhances neovascularization.Human placenta-derived adherent cell treatment of experimental stroke promotes functional recovery after stroke in young adult and older rats.Neurological deficits in mice with profound biotinidase deficiency are associated with demylination and axonal degenerationNiaspan reduces high-mobility group box 1/receptor for advanced glycation endproducts after stroke in type-1 diabetic ratsIdentification of two immortalized cell lines, ECV304 and bEnd3, for in vitro permeability studies of blood-brain barrier.D-galactose-caused life shortening in Drosophila melanogaster and Musca domestica is associated with oxidative stress.D-galactose injured neurogenesis in the hippocampus of adult mice.GM1 ganglioside prevented the decline of hippocampal neurogenesis associated with D-galactose.D-galactose toxicity in mice is associated with mitochondrial dysfunction: protecting effects of mitochondrial nutrient R-alpha-lipoic acid.Chronic systemicD-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: Protective effects of R-α-lipoic acidAdministration of Downstream ApoE Attenuates the Adverse Effect of Brain ABCA1 Deficiency on Stroke
P50
Q24642405-04EE517B-BC2B-4669-9314-4C5A688CEA95Q33761185-2FE01926-2FC2-4A6C-98D4-11A43DD739C0Q33912735-9D7FDAE3-281E-44F9-81A5-4B298FD02450Q35043950-6055C713-D239-4A1B-A924-4DBA23C92FCBQ37001662-48ACDAE3-4ECA-4E71-AB83-1BC24DC1198DQ37500528-707C4F8A-9EEB-4DAF-A8DA-7E2A09F1479AQ37675615-A2D8CAF4-04E4-43FB-BC11-E7046798341AQ40478584-AFF148E2-7B74-4F4F-A466-87AE663FCB01Q43818035-22A31D77-F2AE-4326-8B88-149BBDBA88C0Q45152807-7D920551-0E65-4CDF-8CF6-FEA532FF337FQ46566295-3A832481-9663-4F48-BC2D-66F1614561A9Q46628342-70A118DE-EDAE-4094-BCD5-95C9CD7366BFQ48181571-020587F2-2DCC-4D3F-BB95-0A9290A6465CQ56093363-6B51360E-5E6E-4D63-863C-2C3545AD51B0Q58108647-C09DA27E-94ED-46F0-A972-64F9D6810253
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Xu Cui
@ast
Xu Cui
@en
Xu Cui
@es
Xu Cui
@nl
type
label
Xu Cui
@ast
Xu Cui
@en
Xu Cui
@es
Xu Cui
@nl
prefLabel
Xu Cui
@ast
Xu Cui
@en
Xu Cui
@es
Xu Cui
@nl
P106
P1153
15828853300
55509500500
P31
P496
0000-0002-6937-6191